ライフサイエンスコーパス: allogeneic transplant

1 ng lavages of mice given either syngeneic or allogeneic transplant.

2 mission is the prerequisite for a successful allogeneic transplant.

3 ogical mechanisms in the presence of a fully allogeneic transplant.

4 nsplantation, followed by a nonmyeloablative allogeneic transplant.

5 cell immune response to an H-Y antigen after allogeneic transplant.

6 elopment of typical microvascular lesions in allogeneic transplants.

7 n used as stem cells for both autologous and allogeneic transplants.

8 ls are necessary for initiating rejection of allogeneic transplants.

9 stitution of hematopoiesis in autologous and allogeneic transplants.

10 are upregulated in rejected versus accepted allogeneic transplants.

11 ients who would not qualify for conventional allogeneic transplants.

12 ative to bone marrow for patients undergoing allogeneic transplants.

13 , n=3, P<0.01) compared with vehicle-treated allogeneic transplants.

14 in the lymphoid tissue, such as viruses and allogeneic transplants.

15 all were previously treated and two received allogeneic transplants.

16 t or relapsing disease after T-cell-depleted allogeneic transplants.

17 Mortality was significantly higher in allogeneic transplants (55.1%, p < 0.001) and in those w

18 oma patients who underwent reduced-intensity allogeneic transplants, 66.3% had responses, most of whi

19 We studied 19,229 patients who received allogeneic transplants (97.2 percent) or syngeneic trans

20 Four/10 patients with prior allogeneic transplant achieved at least PR.

21 nhibitory receptor ILT2 and its ligands, and allogeneic transplant-activated MDSCs were obtained in m

22 Allogeneic transplant and higher APACHE III scores, but

23 uced T cells can control the rejection of an allogeneic transplant and suggests that T-cell Foxp3 gen

24 eared the P. carinii but only the mice given allogeneic transplants and anti-IFNgamma had increased l

25 Following reciprocal MHC-disparate allogeneic transplants and during de novo NK-cell recove

26 death rate, complete remission rate, use of allogeneic transplants, and overall survival in AML (non

27 sease is the major risk of reduced-intensity allogeneic transplants, and treatment methods need refin

28 es were 66% in TBI+day 4 vs. 0% in TBI+day 0 allogeneic transplanted animals by day +60 (P<0.001).

29 raftment between the TBI+day 0 and TBI+day 4 allogeneic transplanted animals.

30 In the older CLL patients, nonmyeloablative allogeneic transplants are better tolerated than myeloab

31 Nonmyeloablative allogeneic transplants are less effective in heavily dis

32 Reduced-intensity allogeneic transplants are promising, increasingly used

33 among 1418 patients who received their first allogeneic transplants at our center in Seattle in the p

34 d a unique profile was detected in rejecting allogeneic transplants (BALB/c --> C57BL/6) as compared

35 In allogeneic transplants, both donor and recipient CD73 we

36 tients with myeloid malignancies who need an allogeneic transplant, but lack a suitable sibling donor

37 Therefore, complete tolerance to an allogeneic transplant can only be achieved if all cellul

38 ell as rejection and regulatory tolerance of allogeneic transplants, can occur in recipient mice lack

39 In some of the allogeneic transplants, CD8+ lymphocytes were depleted b

40 t who has failed imatinib but has a possible allogeneic transplant donor, should one offer dasatinib

41 ab vedotin has been evaluated as a bridge to allogeneic transplant for patients refractory to convent

42 d with MPA 40 mg/kg per 24 hr, and untreated allogeneic transplants for 6 months (n=14 in each group)

43 arrow transplants provide the alternative to allogeneic transplants for patients lacking an HLA-match

44 t-AML (n = 545) or t-MDS (n = 323) receiving allogeneic transplants from 1990 to 2004.

45 g syngeneic transplants (group 1), untreated allogeneic transplants (group 2), allogeneic transplants

46 Recipients of allogeneic transplants had a higher probability of devel

47 Overall, reduced-intensity allogeneic transplants have been well tolerated and have

48 t-versus-host disease (GVHD) prophylaxis for allogeneic transplant in patients conditioned with a fra

49 ly 40 published reports of reduced-intensity allogeneic transplants in lymphomas.

50 among 1148 patients who received their first allogeneic transplants in the period from 2003 through 2

51 define better the role of reduced-intensity allogeneic transplants in treating lymphomas.

52 erred source of stem cells for many types of allogeneic transplant, in which matched related donors a

53 nt-related morbidity and mortality following allogeneic transplant, including management of acute and

54 Granzyme B and FasL were expressed in all allogeneic transplants, including those depleted of CD8+

55 Dose-reduced allogeneic transplant is a therapeutic alternative for p

56 ation of hematopoietic stem cells (HSCs) for allogeneic transplants is common in the clinical setting

57 at allow prolonged survival of syngeneic and allogeneic transplanted islets in diabetic BALB/c and NO

58 Reduced renal binding of 99mTc-FGF-1 in the allogeneic transplanted kidney was consistent with decre

59 Allogeneic transplant led to donor-recipient chimerism i

60 Because an allogeneic transplanted liver may induce tolerance to it

61 Notably, PBC recurs in an allogeneic transplanted liver, suggesting generic rather

62 lymphocytic leukemia (CLL) who relapse after allogeneic transplant may achieve durable remission foll

63 ells, which are generally thought to protect allogeneic transplants, may actually be potent facilitat

64 d PBSC maintain their GVL effect in a murine allogeneic transplant model (B6 --> B6D2F1).

65 Gy total body irradiation-based regimens and allogeneic transplants (MUD, n = 38; UCB, n = 15; mismat

66 Allogeneic transplant of purified hematopoietic stem cel

67 After autologous or allogeneic transplants of peripheral blood stem cells (P

68 Thirty-seven patients received allogeneic transplants, of which 18 were T-cell-depleted

69 gene correction either by matched littermate allogeneic transplant or autologous gene therapy were ev

70 to their potential to support autologous and allogeneic transplant paradigms.

71 Thirty-two allogeneic transplant patients and their donors were imm

72 ound in post-DLI responders and not in other allogeneic transplant patients or healthy donors.

73 with donor genotype have been identified in allogeneic transplant patients; however, the donor contr

74 .F5 alone given IV or s.c. (groups 3 and 4), allogeneic transplants plus donor splenocyte preconditio

75 untreated allogeneic transplants (group 2), allogeneic transplants plus multiple doses of AH.F5 alon

76 al study showed that rituximab therapy after allogeneic transplant prevented proteinuria possibly ass

77 and Marrow Transplantation, one-third of the allogeneic transplant procedures for MDS were performed

78 y was 28% in autologous compared with 70% in allogeneic transplant recipients (p = 0.0040).

79 eptor (KIR) gene expression in NK cells from allogeneic transplant recipients and their donors.

80 t-related distress was slower to recover for allogeneic transplant recipients and those with less soc

81 rogate for NETs in 103 consecutive pediatric allogeneic transplant recipients at day 0, +14, +30, +60

82 We confirmed that allogeneic transplant recipients had an impaired reconst

83 the prevaccine and postvaccine titers of 292 allogeneic transplant recipients who were immunized with

84 udied a multi-institutional cohort of 28 874 allogeneic transplant recipients with 189 solid malignan

85 Allogeneic transplant recipients with graft-versus-host

86 We conclude that allogeneic transplant recipients with GVHD have (1) incr

87 ompared with infected control mice, infected allogeneic transplant recipients with GVHD showed increa

88 However, infected allogeneic transplant recipients with GVHD showed lower

89 Anti-TGF-beta treatment of allogeneic transplant recipients with GVHD significantly

90 alveolar lavage (BAL) fluid of mock-infected allogeneic transplant recipients with GVHD, which increa

91 the increased severity of HSV-1 pneumonia in allogeneic transplant recipients with GVHD.

92 2 transgenic) were used as T cell donors for allogeneic transplant recipients, and graft-vs-host dise

93 tion of life-threatening viral infections in allogeneic transplant recipients, demonstrated safety an

94 tion of Clr-b(-/-) BM cells also occurred in allogeneic transplant recipients, where it was reversed

95 onor (n = 177) and unrelated-donor (n = 106) allogeneic transplant recipients.

96 in part, the functional immunodeficiency in allogeneic transplant recipients.

97 s can reduce the incidence of CMV disease in allogeneic transplant recipients.

98 on of tumor immunity and the amelioration of allogeneic transplant rejection.

99 Mice that received allogeneic transplant showed an increase in nuclear 5-LO

100 currently ranges from vaccine development to allogeneic transplant strategies designed to induce a gr

101 These data indicate that allogeneic transplant survivors, particularly those irra

102 Skin samples from tolerant long-term allogeneic transplanted, syngeneic transplanted, rejecte

103 r timing of intubation, or the percentage of allogeneic transplants that were not HLA-identical.

104 major histocompatibility barriers show that allogeneic transplanted thymi are not rejected, and allo

105 on is limited because of immune rejection of allogeneic transplanted tissue and potential adverse sid

106 effector T cells and Tregs serve to prevent allogeneic transplant tolerance.

107 n and fibrogenesis in syngeneic transplants, allogeneic transplants treated with MPA 40 mg/kg per 24

108 Forty-one consecutive allogeneic transplants were performed on patients with a

109 MCMV D+/R- and D-/R- allogeneic transplants were performed with cyclosporine

110 The role of allogeneic transplant with nonmyeloablative conditioning

111 allow the induction of specific tolerance to allogeneic transplants without affecting other immune fu